Three recently-diagnosed ALS patients from the Netherlands have created the first ever ALS-specific investment fund targeted at developing a cure for the debilitating and fatal disease. The founders are also seasoned entrepreneurs, including a serial entrepreneur whose company received an award last year for fastest growing company in Holland, the managing director of an investment company, and an experienced advisor to Fortune 500 companies. The team aims to raise €100 million from impact investors rather than the traditional pharmaceutical/biotech venture capital investors. Although they are just getting started, they have already successfully launched the most extensive global genetic research study in ALS, called Project MinE.
Click here to read more.